SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on August 7, 2012. The registrant is a Colorado corporation headquartered in Castle Rock, CO. The filing reports a specific corporate event rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and does not contain financial statements or performance data.
Material Changes and Events
- Regulatory Submission: On August 7, 2012, the Company submitted a Pre-IDE (Investigational Device Exemption) Information Package to the U.S. Food and Drug Administration (FDA).
- Product Focus: The submission pertains to the AppyScore Appendicitis Test System.
- Documentation: The associated press release is filed as Exhibit 99.1 to this Form 8-K.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or a discussion of risks and contingencies beyond the context of the FDA submission. No unusual items or financial contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the status of the Pre-IDE submission for the AppyScore Appendicitis Test System with the FDA.
- Review the full text of the press release (Exhibit 99.1) for details on the test system's development stage.
- Confirm the Company's current financial position through its most recent 10-K or 10-Q filings, as this 8-K contains no financial data.
- Monitor for future filings regarding FDA feedback or approval of the Pre-IDE package.